| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/1744666X.1.4.511 |
| P698 | PubMed publication ID | 20477595 |
| P2093 | author name string | J Labenz | |
| S Miehlke | |||
| A Morgner-Miehlke | |||
| Ku Petersen | |||
| P2860 | cites work | Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification | Q24670182 |
| Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy | Q28166768 | ||
| Prevalence of gastro-oesophageal reflux disease in general practice | Q28192956 | ||
| Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding | Q28213463 | ||
| Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs | Q31129007 | ||
| Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease | Q31404948 | ||
| Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety | Q31987899 | ||
| Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months | Q32026591 | ||
| Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. | Q33178529 | ||
| Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis | Q33423526 | ||
| Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs | Q33487903 | ||
| Importance of pH control in the management of GERD. | Q33602987 | ||
| Effects of liver disease on pharmacokinetics. An update | Q33789233 | ||
| A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole | Q34174536 | ||
| Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase | Q34252248 | ||
| Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician | Q34279878 | ||
| Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics | Q34311576 | ||
| Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole | Q34320782 | ||
| Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies | Q45240444 | ||
| Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis | Q45264297 | ||
| A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers | Q45289833 | ||
| Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. | Q46024279 | ||
| A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study | Q46383718 | ||
| Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study | Q46424960 | ||
| Symptoms in gastro-oesophageal reflux disease | Q46905458 | ||
| Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. | Q52067661 | ||
| Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. | Q53930659 | ||
| Spezifikation der molekularen Chiralität | Q56657053 | ||
| Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole | Q34340193 | ||
| Omeprazole: the first proton pump inhibitor | Q34371612 | ||
| Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis | Q34409644 | ||
| Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease | Q34523308 | ||
| Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities | Q34549376 | ||
| Review article: Esomeprazole--enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion | Q35080058 | ||
| Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis | Q35759113 | ||
| Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease | Q35857847 | ||
| Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease | Q36011773 | ||
| Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study | Q39376321 | ||
| The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole | Q39377527 | ||
| 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms | Q39381725 | ||
| Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease — an analysis based on the ProGERD initiative | Q39389320 | ||
| Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms | Q39390621 | ||
| Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis | Q39412138 | ||
| Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole | Q39438244 | ||
| Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders | Q40729290 | ||
| Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole | Q41128197 | ||
| Structural aspects of the gastric H,K ATPase | Q41666216 | ||
| Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man | Q41950324 | ||
| Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study | Q42602143 | ||
| Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study | Q42641566 | ||
| Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. | Q42693997 | ||
| Pharmacokinetic study of esomeprazole in the elderly | Q43564480 | ||
| The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety | Q43650344 | ||
| Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole | Q43742706 | ||
| One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease | Q43821891 | ||
| Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study | Q43890008 | ||
| Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis | Q43939369 | ||
| Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies | Q43957391 | ||
| Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. | Q43957394 | ||
| Pharmacokinetic study of esomeprazole in patients with hepatic impairment | Q43976464 | ||
| Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months | Q44097759 | ||
| The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. | Q44186321 | ||
| A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole | Q44402560 | ||
| Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects | Q44596961 | ||
| Esomeprazole‐based one‐week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance | Q44611982 | ||
| Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis | Q44654789 | ||
| Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers | Q44703399 | ||
| Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism | Q44792952 | ||
| Intravenous esomeprazole | Q44826199 | ||
| Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough | Q44895190 | ||
| Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study | Q45009904 | ||
| Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms | Q45045271 | ||
| A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects | Q45172356 | ||
| P433 | issue | 4 | |
| P921 | main subject | esomeprazole | Q553223 |
| P304 | page(s) | 511-527 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Esomeprazole: potent acid suppression in the treatment of acid-related disorders | |
| P478 | volume | 1 |
Search more.